Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells

E. Mrak, I. Villa, R. Lanzi, M. Losa, F. Guidobono, A. Rubinacci

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

It is presently thought that osteoprotegerin (OPG) is a cytokine involved in the regulation of osteoblast/osteoclast crosstalk and maintenance of bone mass. Recent studies showed that GH replacement therapy in GH-deficient patients was able to induce a significant increase of OPG in the plasma, as well as in the cortical and the trabecular bone. In order to determine whether GH could directly modulate OPG secretion, the effect of GH on human osteoblast-like cells (hOB) in primary culture was studied. After detecting the presence of the mRNA for the GH receptor (GHR) by RT-PCR, hOB were exposed to increasing concentrations of GH, from 0.1 to 25 ng/ml, for 24 h. The results showed that GH exposure was able to stimulate OPG secretion in a concentration-dependent manner. In addition, the OPG mRNA levels were increased, indicating that the hormone has a stimulatory effect on gene expression. The stimulatory effect on OPG expression and production was prevented by exposing the cells to tyrphostin AG490 (10 μM), an inhibitor of Janus kinase 2, which is one of the kinases involved in the intracellular pathway activated by the binding of GH to its receptor. Similar results were obtained when the cells were exposed to a receptor antagonist of GH, pegvisomant at 50 nM. GH exposure neither induced an increase in IGF-I expression nor secretion in hOB. These results suggest that the stimulation of OPG production induced by GH in hOB is specific and receptor mediated and further support the view that GH is able to modulate bone remodeling by directly influencing osteoblast-osteoclast crosstalk.

Original languageEnglish
Pages (from-to)639-645
Number of pages7
JournalJournal of Endocrinology
Volume192
Issue number3
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Osteoprotegerin
Osteoblasts
Growth Hormone
Osteoclasts
Janus Kinase 2
Tyrphostins
Messenger RNA
Primary Cell Culture
Bone Remodeling
Insulin-Like Growth Factor I
Phosphotransferases
Maintenance
Hormones
Cytokines
Gene Expression
Bone and Bones
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Endocrinology

Cite this

Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells. / Mrak, E.; Villa, I.; Lanzi, R.; Losa, M.; Guidobono, F.; Rubinacci, A.

In: Journal of Endocrinology, Vol. 192, No. 3, 03.2007, p. 639-645.

Research output: Contribution to journalArticle

@article{83ead752dcd348e9a63ffa7abc55f87a,
title = "Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells",
abstract = "It is presently thought that osteoprotegerin (OPG) is a cytokine involved in the regulation of osteoblast/osteoclast crosstalk and maintenance of bone mass. Recent studies showed that GH replacement therapy in GH-deficient patients was able to induce a significant increase of OPG in the plasma, as well as in the cortical and the trabecular bone. In order to determine whether GH could directly modulate OPG secretion, the effect of GH on human osteoblast-like cells (hOB) in primary culture was studied. After detecting the presence of the mRNA for the GH receptor (GHR) by RT-PCR, hOB were exposed to increasing concentrations of GH, from 0.1 to 25 ng/ml, for 24 h. The results showed that GH exposure was able to stimulate OPG secretion in a concentration-dependent manner. In addition, the OPG mRNA levels were increased, indicating that the hormone has a stimulatory effect on gene expression. The stimulatory effect on OPG expression and production was prevented by exposing the cells to tyrphostin AG490 (10 μM), an inhibitor of Janus kinase 2, which is one of the kinases involved in the intracellular pathway activated by the binding of GH to its receptor. Similar results were obtained when the cells were exposed to a receptor antagonist of GH, pegvisomant at 50 nM. GH exposure neither induced an increase in IGF-I expression nor secretion in hOB. These results suggest that the stimulation of OPG production induced by GH in hOB is specific and receptor mediated and further support the view that GH is able to modulate bone remodeling by directly influencing osteoblast-osteoclast crosstalk.",
author = "E. Mrak and I. Villa and R. Lanzi and M. Losa and F. Guidobono and A. Rubinacci",
year = "2007",
month = "3",
doi = "10.1677/joe.1.07073",
language = "English",
volume = "192",
pages = "639--645",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "BioScientifica Ltd.",
number = "3",

}

TY - JOUR

T1 - Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells

AU - Mrak, E.

AU - Villa, I.

AU - Lanzi, R.

AU - Losa, M.

AU - Guidobono, F.

AU - Rubinacci, A.

PY - 2007/3

Y1 - 2007/3

N2 - It is presently thought that osteoprotegerin (OPG) is a cytokine involved in the regulation of osteoblast/osteoclast crosstalk and maintenance of bone mass. Recent studies showed that GH replacement therapy in GH-deficient patients was able to induce a significant increase of OPG in the plasma, as well as in the cortical and the trabecular bone. In order to determine whether GH could directly modulate OPG secretion, the effect of GH on human osteoblast-like cells (hOB) in primary culture was studied. After detecting the presence of the mRNA for the GH receptor (GHR) by RT-PCR, hOB were exposed to increasing concentrations of GH, from 0.1 to 25 ng/ml, for 24 h. The results showed that GH exposure was able to stimulate OPG secretion in a concentration-dependent manner. In addition, the OPG mRNA levels were increased, indicating that the hormone has a stimulatory effect on gene expression. The stimulatory effect on OPG expression and production was prevented by exposing the cells to tyrphostin AG490 (10 μM), an inhibitor of Janus kinase 2, which is one of the kinases involved in the intracellular pathway activated by the binding of GH to its receptor. Similar results were obtained when the cells were exposed to a receptor antagonist of GH, pegvisomant at 50 nM. GH exposure neither induced an increase in IGF-I expression nor secretion in hOB. These results suggest that the stimulation of OPG production induced by GH in hOB is specific and receptor mediated and further support the view that GH is able to modulate bone remodeling by directly influencing osteoblast-osteoclast crosstalk.

AB - It is presently thought that osteoprotegerin (OPG) is a cytokine involved in the regulation of osteoblast/osteoclast crosstalk and maintenance of bone mass. Recent studies showed that GH replacement therapy in GH-deficient patients was able to induce a significant increase of OPG in the plasma, as well as in the cortical and the trabecular bone. In order to determine whether GH could directly modulate OPG secretion, the effect of GH on human osteoblast-like cells (hOB) in primary culture was studied. After detecting the presence of the mRNA for the GH receptor (GHR) by RT-PCR, hOB were exposed to increasing concentrations of GH, from 0.1 to 25 ng/ml, for 24 h. The results showed that GH exposure was able to stimulate OPG secretion in a concentration-dependent manner. In addition, the OPG mRNA levels were increased, indicating that the hormone has a stimulatory effect on gene expression. The stimulatory effect on OPG expression and production was prevented by exposing the cells to tyrphostin AG490 (10 μM), an inhibitor of Janus kinase 2, which is one of the kinases involved in the intracellular pathway activated by the binding of GH to its receptor. Similar results were obtained when the cells were exposed to a receptor antagonist of GH, pegvisomant at 50 nM. GH exposure neither induced an increase in IGF-I expression nor secretion in hOB. These results suggest that the stimulation of OPG production induced by GH in hOB is specific and receptor mediated and further support the view that GH is able to modulate bone remodeling by directly influencing osteoblast-osteoclast crosstalk.

UR - http://www.scopus.com/inward/record.url?scp=33947394915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947394915&partnerID=8YFLogxK

U2 - 10.1677/joe.1.07073

DO - 10.1677/joe.1.07073

M3 - Article

C2 - 17332531

AN - SCOPUS:33947394915

VL - 192

SP - 639

EP - 645

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 3

ER -